Clinical Trial Update: The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fondaparinux (GSK576428) for acute pulmonary embolism in Japanese patients has completed. Results were posted in December 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Fondaparinux (Arixtra) (Fondaparinux sodium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Embolism, Pulmonary | Phase 3 | Status: COMPLETED | Results posted: 2009-12-10